Pamicogrel (Kanebo)

  • IDrugs. 1999 Sep;2(9):938-42.
P Light  1
Affiliations
  • 1. Department of Pharmacology and Therapeutics, University of Calgary, 3330 Hospital Drive, Alberta, Canada. [email protected]
PMID: 16121308
Abstract

Pamicogrel is a cyclooxygenase inhibitor with platelet anti-aggregatory properties which is under development by Kanebo for chronic arterial occlusion. It also has potential in both prophylaxis and treatment of ischemic brain injury. An NDA was submitted in Japan in April 1997. The effects of the drug on platelet aggregation were originally disclosed in EP-00159677, while the later European patent, EP-00560136, claims its use in brain dysfunction induced by hypoxia arising from disturbance of cerebral circulation, such as cerebral hemorrhage or cerebral infarction.

Products